Altoida is a pioneering company in digital biomarker development for neurological diseases, leveraging augmented reality and machine learning. Its advanced technology platform provides unbiased assessments of an individual’s cognitive and functional abilities, identifies symptomatic impairments from amyloid pathology, and predicts potential progression toward Alzheimer’s disease.

In brain health, Altoida is setting a new standard through Precision Neurology, transforming how brain function is measured and neurological conditions are diagnosed—all via a smartphone or tablet.

With over two decades of research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI), Altoida stands as a leader in this emerging field.